Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — ASEAN Regional Healthcare Conference by DBS (August 2020)
36 slides from Hyphens Pharma International's conference presentation, Aug 3, 2020
Slide 1: General Announcement: Corporate Presentation at ASEAN Regional Healthcare Conference
8/3/2020 General Announcement::CORPORATE PRESENTATION AT ASEAN REGIONAL HEALTHCARE CONFERENCE BY DBS GENERAL ANNOUNCEMENT::CORPORATE PRESENTATION AT ASEAN REGIONAL HEALTHCARE CONFERENCE BY DBS Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIM
Slide 2: Attachments
8/3/2020 General Announcement::CORPORATE PRESENTATION AT ASEAN REGIONAL HEALTHCARE CONFERENCE BY DBS Attachments Hyphens%20Presentation%20Deck_DBS_030820.pdf Total size =3261K MB https://links.sgx.com/1.0.0/corporate-announcements/7TYO5BD5731UFM9T/220e5a9063f52c0854cc4c6413800f415ca8c51818fa4c52fcb1
Slide 3: Hyphens Pharma International Limited
Hyphens Pharma International Limited Singapore’s Leading Specialty Pharma & Consumer Healthcare Group SGX: 1J5, Bloomberg: HYP:SP
Slide 4: Our Strategic Focus
OUR STRATEGIC FOCUS ASEAN’s Leading Long-Term Goal Pharmaceuticals & Asia’s No. 1 Consumer Healthcare Skin Health Group Company
Slide 5: Company Snapshot
COMPANY SNAPSHOT LISTED ON 18 MAY THE 2018 SGX-CATALIST 3 CORE 2019 REVENUE 5 COUNTRIES BUSINESSES S$119 MILLION 250 EMPLOYEES 15 of our products are sold every minute!
Slide 6: 20 Years of Exceptional Growth
20 YEARS OF EXCEPTIONAL GROWTH Sales revenue increased >12x since 1998 Sales ~ S$120m Sales < S$10m 2018 2016 1998 2011 2001 2004 2007 Acquired Acquired Ocean Health Pan-Malayan Launched Ceradan®, our first proprietary Acquired product Hyphens Pharma
Slide 7: Our Regional Presence
OUR REGIONAL PRESENCE SINGAPORE 48.2% VIETNAM 39.1% Bangladesh Hong Kong MALAYSIA 6.7% Oman Philippines Myanmar Vietnam Cambodia Brunei OTHERS 6.0% Malaysia Singapore Indonesia Direct Presence, Marketing & Distribution Network Marketing & Distribution Network Based on FY2019 revenue
Slide 8: Our Business Segments
OUR BUSINESS SEGMENTS Specialty Pharma Principals 55% Proprietary Brands 12% Medical Hypermart and Digital 33% Based on FY2019 revenue
Slide 9: Specialty Pharma Principals
SPECIALTY PHARMA PRINCIPALS What We Do 1. We handle specialised products, under exclusive agreements with our principals, mainly from Europe. 2. We register and hold product licenses with local authorities. 3. We promote these products through medical representatives to specialists and GPs.
Slide 10: Our Specialty Pharma Products
OUR SPECIALTY PHARMA PRODUCTS Interventional Cardiology Neonatology Rheumatology (Biosensors Coronary Stents) Gastroenterology Otorhinolaryngology Allergy Contrast Media Ophthalmology Family Medicine Neuroscience & Psychiatry
Slide 11: Contrast Media Products
CONTRAST MEDIA PRODUCTS GUERBET – XENETIX® DOTAREM® LIPIODOL® Our products are used for: • X-Rays • CT Scans • MRI Participation in Scientific Congresses years of 25 working relationship 2019 Revenue Contribution: 13% Booth Presence Symposiums
Slide 12: Proprietary Brands
PROPRIETARY BRANDS What We Do 1. We are the product owner, and the world is our market. 2. We engage in product development. 3. We contract manufacture these products, which bear our trademarks.
Slide 13: Brands We Own
BRANDS WE OWN NO. 1 CLINICALLY WINNER TOP OF MIND BRAND PROVEN Superbrands By Private Photoaging Status Dermatologists* & Acne Scars since 2004 *IQVIA 2018 Q3 Survey on Top-of-Mind Awareness on 31 Private Dermatologists in Singapore
Slide 14: pH balanced emollient
An advanced emollient with pH balanced formulation with a UK patent & pending in 13 other countries/ region
Slide 15: Atopic Dermatitis Treatment Market Size (USD)
ATOPIC DERMATITIS TREATMENT MARKET SIZE (USD) Market Report from Future Market Insights, 2017 Global: $5.8B Global: $24B ASEAN $596M ASEAN $210M
Slide 16: Medical Hypermart and Digital
MEDICAL HYPERMART AND DIGITAL What We Do 1. We are a wholesaler of pharmaceutical products and medical supplies. 2. We cater largely to private clinics and pharmacies. 3. We have > 3,000 customers and > 4,000 items in our inventory 4. We also have a B2B e-commerce platform that facilitates 24/7 orde
Slide 17: Medical Hypermart and Digital
MEDICAL HYPERMART AND DIGITAL 1st pharmaceutical wholesaler in Singapore to establish an online platform and capture new digital opportunities MORE THAN YEARS HERITAGE BRAND
Slide 18: Business Highlights in 1Q2020
BUSINESS HIGHLIGHTS in 1Q2020
Slide 19: Impact from COVID-19
IMPACT FROM COVID-19 • Impact on operations - Continued to operate as part of essential services - Increase in supply lead time and freight costs • Impact on financial position - Strong cash position and operating cash inflow - Good position to seize opportunities • Pledging support - Committing S$1
Slide 20: Going Digital
GOING DIGITAL are now available on
Slide 21: Going Digital: Well liked by consumers
GOING DIGITAL Well liked by consumers
Slide 22: Going Digital: Engaging medical professionals
GOING DIGITAL Engaging medical professionals
Slide 23: Revamped Websites
REVAMPED WEBSITES Wceradan Weer PredecteSSastinns = SenType - Eble Meesgvers - Tee Stowe ferseting Wow Teter Prginy Catadan? Naige Rebuild Your Skin’s Protective Barrier Goes? ome » Welcome to Pan-Malayan == “2! >> The Medical Hypermart ee ede a FQ eon” KEEN TO JOIN? Sabai ea dad on Singapore's Lead
Slide 24: Investing for Growth
INVESTING FOR GROWTH 1• Establishing a broader geographical footprint - Cementing leadership position in Singapore and deepening presence in ASEAN - Expanding international footprint in Asia, Middle East and Africa 2• Investment in proprietary brands - Driving growth of skin health portfolio through
Slide 25: Investing for Growth
INVESTING FOR GROWTH 3• Strengthening specialty pharma portfolio - Launching new specialty pharma products in regional markets - Seeking licensing opportunities for new products 4• Reinforcing medical hypermart and digital segment - Continue to leverage its broad network in the Singapore market - Ex
Slide 26: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 27: Revenue & Profits Growth (Recap)
1 REVENUE & PROFITS GROWTH (RECAP) Revenue (S$’m) Profit After Tax (S$’m) 6.5 6.1 112.7 120.9 119.4 101 5.4 78.3 5.2 5.1 FY2015 FY2016 FY2017 FY2018 FY2019 FY2015 FY2016 FY2017 FY2018* FY2019 * Incl IPO exp S$0.9m
Slide 28: Strong Quarterly Revenue
1.1 STRONG QUARTERLY REVENUE S$’000 35,000 32,737 31,441 30,699 30,000 29,002 27,004 10,134 25,000 10,210 11,403 9,730 9,742 20,000 3,821 3,589 3,638 4,655 15,000 3,426 10,000 18,782 15,634 16,900 15,383 13,836 5,000 0 1Q2019 2Q2019 3Q2019 4Q2019 1Q2020 Specialty Pharma Principals Proprietary Brands
Slide 29: Improving Margins
2 IMPROVING MARGINS 36.0% 35.0% 34.0% 33.0% 32.0% 31.0% 30.0% FY2015 FY2016 FY2017 FY2018 FY2019 1Q2020 GP margin 32.2% 34.8% 32.8% 33.7% 35.7% 34.7% 11.0% 10.0% 9.0% 8.0% 7.0% 6.0% 5.0% 4.0% FY2015 FY2016 FY2017 FY2018 FY2019 1Q2020 Recurring EBITDA margin 8.1% 6.5% 7.2% 7.4% 8.5% 9.9% PBT margin 7
Slide 30: Strong Financial Position & Cash Flow
3 STRONG FINANCIAL POSITION & CASH FLOW S$’000 31 Mar 2020 31 Dec 2019 Total assets 84,031 80,131 Cash & cash equivalents 27,799 26,165 Total liabilities 37,894 36,055 Financial liabilities 720 300 Total equity 46,137 44,076 NAV per share (cents) 15.36 14.67 S$’000 1Q2020 1Q2019 Cashflow from operat
Slide 31: Maintaining Dividend Policy
4 MAINTAINING DIVIDEND POLICY S$’000 Dividend Yield(a) Div / NP(b) FY2019 1 cent 1.9% 46.0% FY2018 0.55 cents 1.0% 30.5% (a) Yield is computed based on total dividends declared for the financial year divided by closing price of S$0.53 @ 27 Jul 2020. (b) At least 30% of Net Profits Attributable to Sh
Slide 32: Management Ownership
5 MANAGEMENT OWNERSHIP Public Float3, 22.0% Inomed Executive Holding¹, Director², 65.3% 12.7% ¹ Owned by Mr. Lim See Wah, CEO and Dr. Tan Kia King, Non- Executive Director ² Mr. Tan Chwee Choon, Executive Director 3 As at 24 July 2020
Slide 33: Active Investor Outreach 2019
ACTIVE INVESTOR OUTREACH 2019 4 8 3 Results Research Research Briefing firms Coverage 4 2 3 Corporate Retail Remisers outreach outreach Luncheon 5 >20 1 5 Investor Fund Online Publications meetings managers Challenge
Slide 34: Research Reports
RESEARCH REPORTS Recommendation: Buy/ Accumulate
Slide 35: Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group Sy Hyphens
Slide 36: Hyphens Pharma International Limited (SGX: 1J5)
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — ASEAN Regional Healthcare Conference by DBS (August 2020) on 6ix